LG Chem Announces Topline Results of LC350189 From the Phase 2 Study (CLUE Study) Promising to Be a New Treatment Alternative With Improved Efficacy and Safety Profiles for Chronic Gout Patients
LC350189 showed significant serum uric acid (sUA)-lowering effects across all dose levels. LC350189 achieved a treatment target of sUA < 5 mg/dL as the primary endpoint at month 3 with all dose groups when compared with placebo, and Febuxostat. LC350189 was sh